Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study.
Monica TangAndrea L SchafferBelinda E KielyBenjamin DanielsChee K LeeRobert J SimesSallie-Anne PearsonPublished in: Breast cancer research and treatment (2021)
The majority of patients receiving (neo)adjuvant trastuzumab had guideline-recommended baseline and on-treatment cardiac assessment. Variations in cardiac assessment predominantly related to system-level factors, such as year of diagnosis and geography, rather than individual patient factors.